ACTS_16Banner_950x267.jpg
Home Awards Speakers Registration Abstracts Sponsors Schedule Hotel

Meet the 2016 Translational Science Meeting Plenary Speakers!

Wednesday, April 13

Dr. PomeroyClaire Pomeroy, MD, MBA, President of the Albert and Mary Lasker Foundation
Opening Plenary Session: A Call to Action: Building a Thriving Biomedical Research Enterprise in 2016
Wednesday, April 13, 5:00 p.m.

Dr. Pomeroy will discuss the current state of funding for biomedical research in the United States and approaches to enhancing the success of the U.S. biomedical research enterprise in 2016.  Her talk focuses on a call to action for medical schools, faculty and students to be proactive in embracing new approaches to advancing research that improves human health.  Topics will include the imperatives to mentor the next generation of scientists, embrace innovative approaches to research, encourage new partnerships, and engage with the public to increase support for research.

Thursday, April 14

Dr Jacob Corn.jpgDr Kathy HudsonJacob Corn, PhD, Managing Director and Scientific Director of the Innovative Genomics Initiative, Faculty at UC Berkeley in the Department of Molecular and Cell Biology
Kathy Hudson, PhD, Deputy Director for Science, Outreach and Policy, NIH
Gene Editing: From Application to Policy
Thursday, April 14, 8:00 a.m.

Gene editing, or the ability to modify DNA sequences, has become more convenient than ever with the discovery of CRISPR/Cas, a bacterial enzyme system that can be adapted to cut specific DNA sequences on demand. Along with exciting new directions for medical research, this technology also raises ethical and regulatory concerns, particularly with regard to the possibility of editing the human genome. Dr. Jacob Corn, one of the leaders in CRISPR/Cas research, and Dr. Kathy Hudson, a specialist in science policy, will discuss the scientific and regulatory aspects of this technology and future directions for this field of research.

Friday, April 15

Chris Austin Josie.png Dr Nathan David.JPGWilliam Skach Photo.jpg

Chris P. Austin, MD, Director, NCATS
Josie Briggs, MD, Director of the National Center for Complementary and Integrative Health
David G. Nathan, MD, President Emeritus, Dana-Farber Cancer Institute; and Robert A. Stranahan Distinguished Professor of Pediatrics and Professor of Medicine, Harvard Medical School
William R. Skach, MD, Cystic Fibrosis Foundation Senior Vice President for Research Affairs
Clinical Translational Science: The Evolving Landscape and Future Frontiers Impacting Human Health
Friday, April 15, 10:45 a.m.

In the spring of 1995, the NIH Director's Panel on Clinical Research, led by Dr. David G. Nathan, was charged with reviewing the status of clinical translational research and its workforce in the United States, with the goal of providing recommendations about how to ensure its effective continuation. The panel's report lay the ground work for the resurgence of clinical translational research and established novel funding priorities and mechanisms to support collaborative science networks, facilitate discovery science, promote community engagement and foster career development. Funding initiatives including the K30 Clinical Research Curriculum Awards,  K series (K23, Health Services K08 & K07)Mentored Career Development Awards, institutional Roadmap K12, launch of the Centers for Translational Science and the 2012 establishment of the National Center for Translational Science (NCATS) have provided a foundation to launch new fields of inquiry including:  translational therapeutics, focused on accelerating the drug discovery and development process as well as drug repurposing; precision medicine, with the initiation of a national cohort study and further encouraged effective collaborative networks, modeled after successful models embodied by organizations such as the Cystic Fibrosis Foundation, in order to more rapidly successfully combat disease and promote human health. Insight into the history of where we have been and how we arrived at this point in time, among the community of translational scientists, will allow us to best chart our course and define priorities for the future.